Resound Nexia vs Signia Pure C&G IX

The Resound Nexia is a premium behind-the-ear prescription hearing aid released in 2023, priced at $4,298. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.0/5, ranking #26 of 36 devices in the Prescription Hearing Aid category. The Nexia demonstrates clear strengths in specific performance areas. Feedback handling is excellent at 5.0/5, scoring 0.29 points above the category average—meaning users can expect reliable stability without whistling during typical daily activities. Own-voice comfort is also a highlight at 3.6/5, measuring 0.85 points above average, which may appeal to those bothered by their voice sounding hollow or boomy in other devices. However, the Nexia shows meaningful limitations in challenging listening environments. Speech in noise performance is low at 1.0/5, falling 0.96 points below the category average of 1.96/5. Speech in quiet scores 3.2/5—solid in absolute terms, though 0.11 points below the category average. Music streaming is mixed at 2.8/5, slightly above average but not a standout. At this price point, several alternatives in the same range deliver stronger overall performance, including the Phonak Sphere Infinio and Oticon Intent. The Nexia may be best suited for users who prioritize own-voice comfort and feedback-free performance over speech clarity in noisy environments, and who value the Resound ecosystem's connectivity features including iPhone and Android streaming with hands-free capability.

The Signia Pure C&G IX is a premium prescription behind-the-ear hearing aid released in 2023, currently available at $3,298. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.1/5, ranking #20 among 36 prescription hearing aids tested. This device demonstrates consistent strength across multiple performance areas. Speech in quiet scored a solid 4.0/5, sitting 0.65 points above the category average. Speech in noise performance, while above the category average by 0.25 points, remains mixed in absolute terms at 2.2/5—a common challenge across prescription devices. Feedback handling is a standout feature, achieving a perfect 5.0/5 and exceeding the already-high category average. Own-voice comfort scores a solid 3.2/5, running 0.45 points above the category average, which suggests good occlusion management. Music streaming performs solidly at 3.0/5, also above average for the category by 0.36 points. The device supports both iPhone and Android streaming along with hands-free functionality. Professional tuning yields meaningful improvement, with the normalized score increasing from 4.0/5 to 4.5/5. Buyers seeking top-tier performance in this price range should note that competitors like the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5) scored higher in our testing. The Pure C&G IX may suit those who prioritize reliable feedback control and balanced everyday performance over maximum speech-in-noise capability.